The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
ApexOnco Front Page
Recent articles
Felmetatug vedotin’s exit could be bad news for Mersana.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
But the new focus on a predictive biomarker could cut the market in half.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
